SEARCH

SEARCH BY CITATION

References

  • ANSANAY, H., SEBBEN, M., BOCKAERT, J. & DUMUIS, A. (1992). Characterization of homologous 5-hydroxytryptamine4 receptor desensitization in colliculi neurons. Mol. Pharmacol., 42, 808816.
  • BACH, T., SYVERSVEEN, T., KVINGEDAL, A.M., KROBERT, K.A., BRATTELID, T., KAUMANN, A.J. & LEVY, F.O. (2001). 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol., 363, 146160.
  • BAILLIE, G.S. & HOUSLAY, M.D. (2005). Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr. Opin. Cell. Biol., 17, 129134.
  • BEATTIE, D.T., SMITH, J.A., MARQUESS, D., VICKERY, R.G., ARMSTRONG, S.R., PULIDO-RIOS, T., MCCULLOUGH, J.L., SANDLUND, C., RICHARDSON, C., MAI, N. & HUMPHREY, P.P. (2004). The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol., 143, 549560.
  • BERTHOUZE, M., AYOUB, M., RUSSO, O., RIVAIL, L., SICSIC, S., FISCHMEISTER, R., BERQUE-BESTEL, I., JOCKERS, R. & LEZOUALC'H, F. (2005). Constitutive dimerization of human serotonin 5-HT4 receptors in living cells. FEBS Lett., 579, 29732980.
  • BLONDEL, O., GASTINEAU, M., DAHMOUNE, Y., LANGLOIS, M. & FISCHMEISTER, R. (1998). Cloning, expression, and pharmacology of four human 5-hydroxytryptamine4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem., 70, 22522261.
  • BLONDEL, O., VANDECASTEELE, G., GASTINEAU, M., LECLERC, S., DAHMOUNE, Y., LANGLOIS, M. & FISCHMEISTER, R. (1997). Molecular and functional characterization of a 5-HT4 receptor cloned from human atrium. FEBS Lett., 412, 465474.
  • BOCKAERT, J., CLAEYSEN, S., COMPAN, V. & DUMUIS, A. (2004). 5-HT4 receptors. Curr. Drug Targets CNS Neurol. Disord., 3, 3951.
  • BRATTELID, T., KVINGEDAL, A.M., KROBERT, K.A., ANDRESSEN, K.W., BACH, T., HYSTAD, M.E., KAUMANN, A.J. & LEVY, F.O. (2004a). Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i). Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 616628.
  • BRATTELID, T., QVIGSTAD, E., LYNHAM, J.A., MOLENAAR, P., AASS, H., GEIRAN, O., SKOMEDAL, T., OSNES, J.B., LEVY, F.O. & KAUMANN, A.J. (2004b). Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmiedeberg's Arch. Pharmacol., 370, 157166.
  • BRIEJER, M.R., BOSMANS, J.P., VAN DAELE, P., JURZAK, M., HEYLEN, L., LEYSEN, J.E., PRINS, N.H. & SCHUURKES, J.A. (2001). The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol., 423, 7183.
  • CARLISLE MICHEL, J.J., DODGE, K.L., WONG, W., MAYER, N.C., LANGEBERG, L.K. & SCOTT, J.D. (2004). PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J., 381, 587592.
  • CASTRO, L., MIALET-PEREZ, J., GUILLEMEAU, A., STILLITANO, F., ZOLK, O., ESCHENHAGEN, T., LEZOUALCh, F., BOCHET, P. & FISCHMEISTER, R. (2005). Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. J. Mol. Cell. Cardiol., 39, 335344.
  • CLAEYSEN, S., SEBBEN, M., BECAMEL, C., BOCKAERT, J. & DUMUIS, A. (1999). Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol., 55, 910920.
  • DODGE, K.L., KHOUANGSATHIENE, S., KAPILOFF, M.S., MOUTON, R., HILL, E.V., HOUSLAY, M.D., LANGEBERG, L.K. & SCOTT, J.D. (2001). mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J., 20, 19211930.
  • EGLEN, R.M., WONG, E.H., DUMUIS, A. & BOCKAERT, J. (1995). Central 5-HT4 receptors. Trends Pharmacol. Sci., 16, 391398.
  • FERGUSON, S.S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev., 53, 124.
  • GALE, J.D., GROSSMAN, C.J., WHITEHEAD, J.W., OXFORD, A.W., BUNCE, K.T. & HUMPHREY, P.P. (1994). GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br. J. Pharmacol., 111, 332338.
  • GARVEY, J.L., KRANIAS, E.G. & SOLARO, R.J. (1988). Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem. J., 249, 709714.
  • GERALD, C., ADHAM, N., KAO, H.T., OLSEN, M.A., LAZ, T.M., SCHECHTER, L.E., BARD, J.A., VAYSSE, P.J., HARTIG, P.R. & BRANCHEK, T.A. (1995). The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J., 14, 28062815.
  • GRAMMER, J.B., ZENG, X., BOSCH, R.F. & KUHLKAMP, V. (2001). Atrial L-type Ca2+-channel, β-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res. Cardiol., 96, 8290.
  • GUO, Z.G., LEVI, R., AARONSON, L.M. & GAY, W.A. (1983). The isolated human pectinate muscle: a reliable preparation of human cardiac tissue. J. Pharmacol Methods, 9, 127135.
  • HANOUZ, J.L., PERSEHAYE, E., ZHU, L., LAMMENS, S., LEPAGE, O., MASSETTI, M., BABATASI, G., KHAYAT, A., BRICARD, H. & GERARD, J.L. (2004). The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade. Anesth. Analg., 99, 16891695.
  • HEUBACH, J.F., RAVENS, U. & KAUMANN, A.J. (2004). Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human β2-adrenoceptors overexpressed in mouse heart. Mol. Pharmacol., 65, 13131322.
  • JAHNEL, U., RUPP, J., ERTL, R. & NAWRATH, H. (1992). Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn-Schmiedebergs Arch. Pharmacol., 346, 482485.
  • JOUBERT, L., HANSON, B., BARTHET, G., SEBBEN, M., CLAEYSEN, S., HONG, W., MARIN, P., DUMUIS, A. & BOCKAERT, J. (2004). New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4(a) receptor splice variant: roles in receptor targeting. J. Cell Sci., 117, 53675379.
  • JUREVICIUS, J. & FISCHMEISTER, R. (1996). cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. U.S.A., 93, 295299.
  • KAUMANN, A., BARTEL, S., MOLENAAR, P., SANDERS, L., BURRELL, K., VETTER, D., HEMPEL, P., KARCZEWSKI, P. & KRAUSE, E.G. (1999). Activation of β2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation., 99, 6572.
  • KAUMANN, A.J. (1990). Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 342, 619622.
  • KAUMANN, A.J. (1994). Do human atrial 5-HT4 receptors mediate arrhythmias Trends Pharmacol. Sci., 15, 451455.
  • KAUMANN, A.J., LYNHAM, J.A. & BROWN, A.M. (1995). Labelling with [125I]-SB 207710 of a small 5-HT4 receptor population in piglet right atrium: functional relevance. Br. J. Pharmacol., 115, 933936.
  • KAUMANN, A.J., LYNHAM, J.A. & BROWN, A.M. (1996). Comparison of the densities of 5-HT4 receptors, β1- and β2-adrenoceptors in human atrium: functional implications. Naunyn-Schmiedebergs Arch. Pharmacol., 353, 592595.
  • KAUMANN, A.J., MURRAY, K.J., BROWN, A.M., SANDERS, L. & BROWN, M.J. (1989). A receptor for 5-HT in human atrium. Br. J. Pharmacol., 98, 664 P.
  • KAUMANN, A.J. & SANDERS, L. (1994). 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade. Naunyn-Schmiedeberg's Arch. Pharmacol., 349, 331337.
  • KAUMANN, A.J. & SANDERS, L. (1998). 5-Hydroxytryptamine and human heart function: the role of 5-HT4 receptors. In 5-HT4 Receptors in the Brain and Periphery, ed. Eglen, R.M. pp. 127148. Georgetown, Tex: RG Landes.
  • KAUMANN, A.J., SANDERS, L., BROWN, A.M., MURRAY, K.J. & BROWN, M.J. (1990). A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol., 100, 879885.
  • KAUMANN, A.J., SANDERS, L., BROWN, A.M., MURRAY, K.J. & BROWN, M.J. (1991). A 5-HT4-like receptor in human right atrium. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 150159.
  • KENAKIN, T. (1995). Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci., 16, 188192.
  • KENAKIN, T.P. & MORGAN, P.H. (1989). Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol. Pharmacol., 35, 214222.
  • KILTS, J.D., AKAZAWA, T., EL MOALEM, H.E., MATHEW, J.P., NEWMAN, M.F. & KWATRA, M.M. (2003). Age increases expression and receptor-mediated activation of Gi in human atria. J. Cardiovasc. Pharmacol., 42, 662670.
  • LANGLOIS, M. & FISCHMEISTER, R. (2003). 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem., 46, 319344.
  • LORRAIN, J., GROSSET, A. & O'CONNOR, S.E. (1992). 5-HT4 receptors, present in piglet atria and sensitive to SDZ 205-557, are absent in papillary muscle. Eur. J. Pharmacol., 229, 105108.
  • MARTIN, N.P., WHALEN, E.J., ZAMAH, M.A., PIERCE, K.L. & LEFKOWITZ, R.J. (2004). PKA-mediated phosphorylation of the β1-adrenergic receptor promotes Gs/Gi switching. Cell. Signal., 16, 13971403.
  • MATTIAZZI, A., GARAY, A. & CINGOLANI, H.E. (1986). Critical evaluation of isometric indexes of relaxation in rat and cat papillary muscles and toad ventricular strips. J. Mol. Cell. Cardiol., 18, 749758.
  • MEDHURST, A.D. & KAUMANN, A.J. (1993). Characterization of the 5-HT4 receptor mediating tachycardia in piglet isolated right atrium. Br. J. Pharmacol., 110, 10231030.
  • MEDHURST, A.D., LEZOUALC'H, F., FISCHMEISTER, R., MIDDLEMISS, D.N. & SANGER, G.J. (2001). Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT–PCR. Brain Res. Mol. Brain Res., 90, 125134.
  • MIALET, J., BERQUE-BESTEL, I., EFTEKHARI, P., GASTINEAU, M., GINER, M., DAHMOUNE, Y., DONZEAU-GOUGE, P., HOEBEKE, J., LANGLOIS, M., SICSIC, S., FISCHMEISTER, R. & LEZOUALC'H, F. (2000). Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br. J. Pharmacol., 129, 771781.
  • MIALET, J., FISCHMEISTER, R. & LEZOUALC'H, F. (2003). Characterization of human 5-HT4(d) receptor desensitization in CHO cells. Br. J Pharmacol., 138, 445452.
  • OUADID, H., SEGUIN, J., DUMUIS, A., BOCKAERT, J. & NARGEOT, J. (1992). Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. Mol. Pharmacol., 41, 346351.
  • PARKER, S.G., TAYLOR, E.M., HAMBURGER, S.A., VIMAL, M. & KAUMANN, A.J. (1995). Blockade of human and porcine myocardial 5-HT4 receptors by SB 203186. Naunyn-Schmiedeberg's Arch. Pharmacol., 353, 2835.
  • PAU, D., WORKMAN, A.J., KANE, K.A. & RANKIN, A.C. (2003). Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic β-adrenoceptor blockade. Br. J. Pharmacol., 140, 14341441.
  • PAU, D., WORKMAN, A., KANE, K. & RANKIN, A. (2005). Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with β-adrenoceptor antagonists. J. Pharmacol. Exp. Ther., 313, 146153.
  • PERRY, S.J., BAILLIE, G.S., KOHOUT, T.A., MCPHEE, I., MAGIERA, M.M., ANG, K.L., MILLER, W.E., MCLEAN, A.J., CONTI, M., HOUSLAY, M.D. & LEFKOWITZ, R.J. (2002). Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science, 298, 834836.
  • PINDON, A., VAN HECKE, G., VAN GOMPEL, P., LESAGE, A.S., LEYSEN, J.E. & JURZAK, M. (2002). Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Gs- and Gi/o-proteins. Mol. Pharmacol., 61, 8596.
  • PINHEIRO, J.C. & BATES, D.M. (2000). Mixed Effects Models in S and S-plus, ed. Chambers, J., Eddy, W., Hardle, W., Sheather, S. & Tierney, L., New York: Springer-Verlag.
  • PINO, R., CERBAI, E., CALAMAI, G., ALAJMO, F., BORGIOLI, A., BRACONI, L., CASSAI, M., MONTESI, G.F. & MUGELLI, A. (1998). Effect of 5-HT4 receptor stimulation on the pacemaker currentIf in human isolated atrial myocytes. Cardiovasc. Res., 40, 516522.
  • PONIMASKIN, E., DUMUIS, A., GAVEN, F., BARTHET, G., HEINE, M., GLEBOV, K., RICHTER, D.W. & OPPERMANN, M. (2005). Palmitoylation of the 5-hydroxytryptamine4(a) receptor regulates receptor phosphorylation, desensitization and β-Arrestin mediated endocytosis. Mol. Pharmacol., 67, 14341443.
  • QVIGSTAD, E., BRATTELID, T., SJAASTAD, I., ANDRESSEN, K.W., KROBERT, K.A., BIRKELAND, J.A., SEJERSTED, O.M., KAUMANN, A.J., SKOMEDAL, T., OSNES, J.B. & LEVY, F.O. (2005). Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc. Res., 65, 869878.
  • RAHME, M.M., COTTER, B., LEISTAD, E., WADHWA, M.K., MOHABIR, R., FORD, A.P., EGLEN, R.M. & FELD, G.K. (1999). Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation, 100, 20102017.
  • RAYMOND, J.R., MUKHIN, Y.V., GELASCO, A., TURNER, J., COLLINSWORTH, G., GETTYS, T.W., GREWAL, J.S. & GARNOVSKAYA, M.N. (2001). Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther., 92, 179212.
  • ROCHAIS, F., VANDECASTEELE, G., LEFEBVRE, F., LUGNIER, C., LUM, H., MAZET, J.L., COOPER, D.M. & FISCHMEISTER, R. (2004). Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J. Biol. Chem., 279, 5209552105.
  • RONDE, P., ANSANAY, H., DUMUIS, A., MILLER, R. & BOCKAERT, J. (1995). Homologous desensitization of 5-hydroxytryptamine4 receptors in rat esophagus: functional and second messenger studies. J. Pharmacol. Exp. Ther., 272, 977983.
  • SANDERS, L. & KAUMANN, A.J. (1992). A 5-HT4-like receptor in human left atrium. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 382386.
  • SANDERS, L., LYNHAM, J.A., BOND, B., DEL MONTE, F., HARDING, S.E. & KAUMANN, A.J. (1995). Sensitization of human atrial 5-HT4 receptors by chronic β-blocker treatment. Circulation, 92, 25262539.
  • SAUDOU, F. & HEN, R. (1994). 5-Hydroxytryptamine receptor subtypes: molecular and functional diversity. Adv. Pharmacol., 30, 327380.
  • SAXENA, P.R. (1995). Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol. Ther., 66, 339368.
  • SCHOEMAKER, R.G., DU, X.Y., BAX, W.A., BOS, E. & SAXENA, P.R. (1993). 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur. J. Pharmacol., 230, 103105.
  • SCHOEMAKER, R.G., DU, X.Y., BAX, W.A. & SAXENA, P.R. (1992). 5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol., 346, 486489.
  • ULENS, C. & TYTGAT, J. (2001). Gi- and Gs-coupled receptors up-regulate the cAMP cascade to modulate HCN2, but not HCN1 pacemaker channels. PflugersArch., 442, 928942.
  • VERBEKE, G. & MOLENBERGHS, G. (2005). Linear Mixed Models in Practice. A SAS-Oriented Approach. Berlin: Springer-Verlag.
  • VILARO, M.T., DOMENECH, T., PALACIOS, J.M. & MENGOD, G. (2002). Cloning and characterization of a novel human 5-HT4 receptor variant that lacks the alternatively spliced carboxy terminal exon. RT–PCR distribution in human brain and periphery of multiple 5-HT4 receptor variants. Neuropharmacology, 42, 6073.
  • VILLALON, C.M., DEN BOER, M.O., HEILIGERS, J.P. & SAXENA, P.R. (1991). Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig. Br. J. Pharmacol., 102, 107112.
  • VONESH, E.F. & CHINCHILLI, V.M. (1997). Linear and Nonlinear Models for the Analysis of Repeated Measurements. New York: Marcel-Dekker.
  • WORKMAN, A.J. & RANKIN, A.C. (1998). Serotonin, If and human atrial arrhythmia. Cardiovasc. Res., 40, 436437.
  • XIANG, Y. & KOBILKA, B. (2003). The PDZ-binding motif of the β2-adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A., 100, 1077610781.
  • ZACCOLO, M. & POZZAN, T. (2002). Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science, 295, 17111715.